Source comparison
Tesamorelin + Ipamorelin Blend Contraindications: Condition Comparison
The table below compares absolute contraindications, relative contraindications, and medication interactions for tesamorelin + ipamorelin blend, detailing the biological mechanism that creates risk and the clinical recommendation for each. Active malignancy or
This comparison does not assign a generated winner or score.
- The table below compares absolute contraindications, relative contraindications, and medication interactions for tesamorelin + ipamorelin blend, detailing the biological mechanism that creates risk and the clinical recommendation for each.
- Active malignancy or cancer history
- Absolute
- GH-stimulated IGF-1 promotes tumor cell proliferation, angiogenesis, and metastasis
- Do not use; consider alternatives without GH pathway involvement
- Uncontrolled diabetes (HbA1c >8.5%)
- GH is a counter-regulatory hormone that raises fasting glucose and worsens insulin resistance
- Stabilize HbA1c <7.5% before initiating; monitor biweekly
- Severe renal impairment (CrCl <30)
- Impaired peptide clearance increases AUC by 340%, causing unpredictable accumulation
- Do not use; no safe dose adjustment available
- Pregnancy or lactation
- Insufficient safety data; GH crosses placenta and appears in breast milk
- Discontinue ≥60 days before conception; use reliable contraception
- Prediabetes (HbA1c 5.7–6.4%)
- Relative
- GH antagonizes insulin, potentially accelerating progression to overt diabetes
- Start at 50% dose; monitor fasting glucose biweekly; titrate slowly
- Obstructive sleep apnea
- GH-induced soft tissue hypertrophy narrows upper airway, raising AHI by ~6 events/hour
- Baseline polysomnography; recheck at week 12; adjust CPAP if needed
- Corticosteroid therapy (≥10mg prednisone)
- Medication interaction
- Glucocorticoids inhibit GH receptor signaling, reducing IGF-1 synthesis by 68%
- Minimal benefit expected; consider alternative therapy or steroid taper
- Insulin or oral hypoglycemics
- GH raises fasting glucose, rendering baseline insulin doses insufficient
- Increase glucose monitoring; anticipate 15–25% insulin dose increase